IM8 90-Day Subscribers Unlock SuperPower Blood Testing for $49 — A 75% Saving on the Standard $199 Price.IM8 and Superpower create the first closed-loop system in consumer health – connecting clinical-grade supplementation with 100+ biomarker blood testing.IM8's Daily Ultimate Essentials will be available in the Superpower supplement marketplace and featured, where biomarker data supports it, as one of Superpower's recommended foundational daily supplements in members' personalized health protocols. NEW YOR ...

Yeung outlined a timeline of growth since launch. He said IM8 began selling online in December 2024 and generated $581,000 in revenue in its first month. In January, the company held a public launch in New York, and Beckham appeared on the TODAY show to promote the product, which Yeung said drove PR and media exposure.On athlete adoption, Yeung cited Aryna Sabalenka, the world’s No. 1 women’s tennis player, saying she took the product for three months before contacting the company. He also said IM8 recently ...

Prenetics Global (NasdaqGM:PRE) FY Conference March 23, 2026 03:00 PM ET Company ParticipantsDanny Yeung - CEO and Co-founderJason Wersland - FounderNate Raabe - Managing PartnerShadi Bakour - Co-founder and CEOShahab Elmi - Founder and CEOConference Call ParticipantsNone - AnalystNone - AnalystNate RaabeAll right, we're missing a panelist here. I think he's talking with Mr. Johnson out there, so he may join us later. We're gonna go ahead and get started here. There'll be people trickling in. My name is Nat ...

Prenetics Global (NasdaqGM:PRE) FY Conference March 23, 2026 11:30 AM ET Company ParticipantsDanny Yeung - Co-Founder and CEOConference Call ParticipantsGeorge Kelly - Managing Director and Senior Research AnalystNone - AnalystNone - AnalystNone - AnalystGeorge KellyHi, everybody. I'm George Kelly with Roth. Excited to have Danny Yeung, who's the Co-Founder and CEO of Prenetics, with me today. We don't have a ton of time, just like 25 minutes. I'll stop every once in a while and take questions if there are ...

Prenetics Global logo Prenetics Global (NASDAQ:PRE) CEO and co-founder Danny Yeung told investors the company delivered what he described as a “breakout growth story” in 2025, driven by the rapid expansion of its IM8 direct-to-consumer supplements business and a broader strategic shift to focus on that brand. 2025 performance and IM8 ramp Yeung said Prenetics generated approximately $92 million in full-year 2025 revenue, inclusive of multiple business units. He attributed the results largely to IM8, whi ...

Prenetics Global Conference Call Summary Company Overview - **Company**: Prenetics Global (NasdaqGM:PRE) - **Key Product**: IM8, a health supplement brand launched in December 2024 - **2025 Revenue**: Approximately $92 million, with IM8 contributing $120 million ARR in its first year of operations [1][2] Financial Performance - **2025 Full Year Revenue**: $92 million, with IM8 generating $120 million ARR [1][2] - **Gross Margins**: 63% for IM8 [2] - **Liquidity**: Approximately $160 million in liquid assets, zero debt [2] - **Divestments**: Sold non-core assets including ACT for $72 million, Europa for $13 million, and Insighta to Tencent for $70 million [2][3] Growth Strategy - **Roadmap to Profitability**: Expected by Q4 2027 [2] - **Market Expansion**: IM8 operates in 31 countries, with the U.S. representing 40% of revenue [3][4] - **Customer Base**: Target demographic is ages 30-60, top 10% of household incomes [20][21] - **Marketing Channels**: Currently focused on Meta and Google, with plans to diversify into TikTok, YouTube, and AppLovin [15][24] Product Development - **New Offerings**: Introduction of a three-month subscription option, increasing average order value to approximately $233 [8][9] - **Product Formulation**: Daily Ultimate Essentials and Daily Ultimate Longevity targeting health and aging [12][13] - **Clinical Trials**: Three new clinical trials planned, including collaboration with Mayo Clinic [27] Customer Acquisition and Retention - **Customer Acquisition Cost (CAC)**: $130, with a 24-month Lifetime Value (LTV) of approximately $480 [6] - **Subscription Rate**: 80% of new customers opt for subscriptions, providing predictable revenue [9] Marketing and Brand Ambassadors - **Ambassadors**: Includes David Beckham, Aryna Sabalenka, and Ollie Bearman, who are also shareholders [10][11] - **Social Media Impact**: A viral video reached 233 million views, enhancing brand visibility [11] Future Outlook - **Revenue Guidance for 2026**: Projected revenue of $180 million-$200 million, representing 300% year-over-year growth [17] - **Market Localization**: Plans to enter new markets with tailored marketing strategies [16] - **Long-term Vision**: Aiming for a billion-dollar valuation, with strong brand recognition and customer loyalty [18] Additional Insights - **Bitcoin Holdings**: Currently holding 510 Bitcoins, treated as a treasury asset [3][30] - **Share Buyback Program**: Announced a $40 million share buyback, with $2.75 million already executed by management [32] Conclusion - Prenetics has successfully transformed into a rapidly growing consumer brand, leveraging strong product offerings, strategic marketing, and a clear path to profitability. The company is well-positioned for future growth with significant cash reserves and a focus on expanding its market presence.

Core Insights - Prenetics Global Limited will participate in the 38th Annual ROTH Conference from March 22nd to March 24th, 2026 [1] - CEO Danny Yeung and President of Americas David Vanderveen will hold one-on-one meetings and participate in a fireside chat and a Consumer Influencer panel discussion during the conference [2] - IM8, Prenetics' flagship brand, has surpassed $100 million in annualized recurring revenue within 11 months of operations and is sold in over 30 countries [4] Company Overview - Prenetics is a leading health sciences company focused on advancing human health and longevity, with its premium brand IM8 co-founded by David Beckham [4] - IM8 combines cutting-edge science with natural ingredients to provide a holistic approach to health, featuring its flagship product, Daily Ultimate Essentials, which replaces 16 different supplements [5] - IM8 is NSF Certified for Sport, non-GMO, vegan, and free from common allergens, artificial flavors, colors, or sweeteners [5]

Core Viewpoint - BNP Paribas has announced its 2030 Strategic Plan for its Asset Management platform, aiming to double pre-tax income by 2030 and achieve a 13% Return on Tangible Equity by 2028 [1][6]. Group 1: Strategic Growth and Financial Goals - The Asset Management platform now manages over €1.6 trillion in assets, with a diversified mix across strategies and distribution channels [2]. - The 2030 plan is built on four strategic growth pillars, targeting approximately €150 million in revenue synergies and around €400 million in cost synergies by 2029 [3][6]. - The financial trajectory from 2025 to 2030 includes a target of ~€350 billion in cumulative net inflows and an annual growth rate of over 5% in assets under management [6]. Group 2: Technological Advancements and Client Services - The platform will enhance its technological and client-servicing capabilities through the deployment of AI across the investment and servicing value chain [4]. - The Investment & Protection Services division aims to meet the evolving needs of individuals, corporates, and institutions, leveraging the scale of the Asset Management business [5]. Group 3: Performance Metrics and Projections - The company projects a revenue CAGR of approximately +4% from 2025 to 2030, primarily driven by the increase in assets under management and synergies [6]. - Operating expenses are expected to remain flat between 2025 and 2030, with an improvement in the cost/income ratio to below 60% by 2030 [6]. - Pre-tax income is anticipated to nearly double by 2030, with a CAGR of about +13% compared to 2025 pro-forma [6].

Core Viewpoint - Prenetics Global Limited has announced a share repurchase program of up to $40 million, reflecting the Board's belief that the current share price does not accurately represent the company's underlying value and growth trajectory [1][5][10] Financial Performance and Capital Allocation - The executive leadership team of Prenetics has invested approximately $2.75 million of personal capital into the company's stock over two recent post-earnings trading windows, indicating strong internal confidence in the company's prospects [2][3][4] - Prenetics has approximately $164 million in total adjusted liquidity and zero debt as of March 1, 2026, positioning the company well to fund growth and the share repurchase program [6][7][8] - The company is targeting revenue between $180 million and $200 million for 2026, with a clear path to adjusted EBITDA profitability by Q4 2027 [5][9][11] Strategic Decisions and Business Focus - Prenetics has completed three strategic divestitures to concentrate on its highest-growth and highest-margin business, IM8, which has been co-founded with David Beckham and is gaining traction in the premium nutrition market [6][11][13] - The share repurchase program is seen as a disciplined choice for capital allocation, allowing the company to return value to shareholders while maintaining sufficient capital for growth [8][10] Market Position and Growth Potential - IM8 has quickly become one of the fastest-growing brands in consumer health, surpassing $100 million in annualized recurring revenue within 11 months of operations and is now sold in over 30 countries [13][14] - The company's enterprise value is approximately $89 million, which is less than 0.5 times IM8's projected revenue for 2026, suggesting that the market is undervaluing the business [5][10]

Core Insights - Prenetics Global Limited (NASDAQ:PRE) reported a remarkable 480% year-over-year revenue increase to $92.4 million for 2025, driven by the success of its IM8 brand, which achieved an annual recurring revenue (ARR) of $120 million within its first year [1][7] - The company has undergone a strategic transformation by divesting non-core assets, including a $70 million cash sale of its stake in Insighta to Tencent, resulting in approximately $171 million in adjusted liquidity and zero debt [2] - Looking ahead to 2026, Prenetics reaffirmed its revenue guidance for IM8 at $180 to $200 million, with an aim for an ARR of up to $300 million by year-end, supported by a shift towards quarterly subscription models [3] Financial Performance - Q4 revenue reached $36.6 million, reflecting a 55% increase over the previous quarter, indicating strong market traction for the IM8 brand co-founded by David Beckham [1] - The average order value has increased to approximately $233 in early 2026, contributing to the anticipated revenue growth [3] Business Strategy - Prenetics is focusing on becoming a pure-play leader in the consumer health and nutrition sector, having ceased all cryptocurrency purchases while maintaining a permanent holding of 510 BTC [2] - The company operates in the health sciences sector, offering health and wellness products under the IM8 brand and providing fulfillment and distribution services for sports nutrition products under the Europa brand [4]